Stakeholder Mapping Canvas for Enterprise AI Products

Every failed enterprise AI deployment I've seen had a stakeholder problem - not a technology problem. Either the champion lost organizational support, a gatekeeper blocked a critical integration, or end users were never consulted and rejected the product on arrival.

Stakeholder mapping is not a one-time kickoff exercise. It's a living map that you update as the deployment evolves. This canvas gives you the tools to build that map: a power/interest grid, a role taxonomy, a communication cadence planner, a RACI matrix, and a worked example.

Section 1 - Power/Interest Grid

Place each stakeholder in one of four quadrants based on their power (authority to approve, block, or allocate resources) and interest (degree to which this product directly affects their work or goals).

| | Low Interest | High Interest | | --- | --- | --- | | High Power | Keep SatisfiedThese stakeholders can block you but aren't directly affected. Examples: CISO (security review), CFO (budget approval), CMO (brand risk). Strategy: low-frequency, high-quality updates. Don't flood them with detail - give them what they need to feel confident. | Manage CloselyThese stakeholders have both authority and skin in the game. They become your Champions or your biggest blockers. Examples: VP of Clinical Operations, Chief Medical Informatics Officer. Strategy: bi-weekly 1:1s, early preview of decisions that affect them, give them credit for wins. | | Low Power | MonitorLow current relevance. But watch for role changes - a nurse manager who moves to VP Clinical Operations takes their attitude toward your product with them. Strategy: include in broadcast communications; don't require their time. | Keep InformedThese are your end users and enthusiasts. They don't have formal authority but they have informal influence. A disengaged end user population is a retention risk. Strategy: user councils, feedback sessions, beta programs. Make them feel heard. |

Canvas Template

For each stakeholder, capture:

| Name | Role/Title | Power (H/M/L) | Interest (H/M/L) | Quadrant | Stance (Champion / Neutral / Skeptic / Blocker) | Key Concern | What They Need from You | | --- | --- | --- | --- | --- | --- | --- | --- | | [Name] | [Title] | [ ] | [ ] | [ ] | [ ] | [e.g., "Will this replace my team?"] | [e.g., Monthly ROI update] | | [Name] | [Title] | [ ] | [ ] | [ ] | [ ] | [ ] | [ ] |

Section 2 - Role Taxonomy

Five roles that appear in almost every enterprise AI deployment. One person can hold multiple roles. Knowing which role someone is playing changes how you engage them.

Champion

Who they are: Internally advocates for the product, introduces you to other stakeholders, defends budget at renewal. Often the person who originally brought you in.

What they need: Wins they can take credit for. Early access to data showing impact. Language to use internally when explaining the product's value.

Risk: Champions leave. Build in a champion succession plan from day one. If your champion is the only person internally championing the product, you have a single point of failure.

Action: Identify 2-3 champions, not just one. Make every champion look good publicly within their organization.

Influencer

Who they are: High-credibility individual whose opinion shapes others' views, even without formal authority. Often a senior clinician, a respected analyst, or a long-tenured manager. If an influencer goes negative on your product, the end users follow.

What they need: Early involvement and genuine input (not fake input). They can tell the difference between "we consulted them" and "we actually listened to them."

Action: Get influencers involved in beta programs and design reviews. Attribute their feedback publicly. Never surprise an influencer with a launch announcement.

Gatekeeper

Who they are: Controls access to something you need: IT for EHR integration, Legal for DUA approval, IRB for clinical validation study approval, Procurement for vendor contracts.

What they need: Their process followed correctly and completely. Gatekeepers are not adversaries - they are process owners. Fighting them costs you time. Mapping their process and respecting it saves you time.

Action: Map every gatekeeper and their process before you start the deployment. Add gatekeeper lead times to your project timeline (legal review: 4-8 weeks; IT security review: 2-4 weeks; IRB: 1-3 months).

Blocker

Who they are: Actively working against the product's deployment or adoption. This may be due to job security concerns, competitive priorities, philosophical objection to AI, or a previous bad experience with a similar product.

What they need: To be understood before you try to convert them. Most blockers have a legitimate concern underneath the resistance. Find it.

Action: Request a 1:1. Don't bring a pitch - bring questions. "Help me understand what would need to be true for this to feel safe to you" is more effective than "let me show you the ROI data."

End User

Who they are: The person who interacts with the product daily. In Life Sciences & Life Sciences & Healthcare AI, this is often a nurse, pharmacist, research coordinator, or data analyst - not the person who bought the product.

What they need: A product that actually helps them do their job. Not just a product their organization paid for.

Risk: The biggest driver of enterprise AI failure is end user rejection - either non-adoption or active workaround. An end user who routes around your product and does the task manually is a churn signal in slow motion.

Action: Conduct user research with end users, not just buyers. Run a 5-user usability study before launch. Check override rates weekly - they tell you more than any survey.

Section 3 - Communication Cadence Planner

Different stakeholders need different information at different frequencies. A CISO does not need your weekly sprint review. An end user does not need your board-level business case. Sending the same update to everyone is a reliable way to get everyone to stop reading your updates.

| Stakeholder / Group | What They Get | Format | Frequency | Channel | Owner | | --- | --- | --- | --- | --- | --- | | Executive Champion (VP+) | Business impact summary, key decisions that need their input, risks requiring their attention | 1-page email + 15-min sync | Bi-weekly | Email + calendar | PM | | Clinical Lead / CMIO | Clinical performance data (accuracy, override rate), patient safety events, feature roadmap with clinical rationale | Structured email with data tables | Monthly | Email | PM + Clinical Informatics | | IT / Integration Team | Upcoming releases that affect integrations, known bugs and workarounds, planned downtime | Technical release notes | With each release | Email + Slack/Teams | Engineering Lead | | Compliance / Legal | Regulatory filing status, security incident reports, policy change requests | Formal memo or email | As needed (plus quarterly review) | Email (tracked) | PM + Compliance | | End Users | New features, tips, known issues and workarounds, how their feedback influenced the product | In-app notification + short email | Monthly | In-app + email | PM | | User Council / Power Users | Beta feature previews, open roadmap discussion, direct feedback sessions | Video call | Quarterly | Zoom / Teams | PM | | [Add row] | [ ] | [ ] | [ ] | [ ] | [ ] |

Section 4 - RACI Matrix for AI Product Decisions

RACI assigns four roles to each decision: Responsible (does the work), Accountable (owns the outcome), Consulted (input required before decision), Informed (notified after decision). For AI products, I've added a fifth: Approver - used specifically for decisions that require formal sign-off (regulatory submission, clinical validation launch, rollback).

| Decision | PM | Engineering Lead | Clinical Lead | ML Lead | Compliance | Customer Exec | End User Rep | | --- | --- | --- | --- | --- | --- | --- | --- | | Feature prioritization | A/R | C | C | C | I | C | C | | Model accuracy threshold (production) | C | C | A | R | C | I | I | | Rollback decision | C | R | A | R | I | I | I | | Regulatory submission | C | C | C | C | A/R | I | I | | New data source approval | C | R | C | C | A | I | I | | Product launch (go/no-go) | R | C | C | C | C | A | I | | User communication (incident) | A/R | C | C | I | C | C | I | | [Add decision] | [ ] | [ ] | [ ] | [ ] | [ ] | [ ] | [ ] |

Key: R = Responsible, A = Accountable, C = Consulted, I = Informed. Each row must have exactly one A.

Section 5 - Worked Example: Clinical Trial Matching AI at an Academic Medical Center

Context: Deploying an NLP-based clinical trial eligibility screener at a large academic medical center. The product scans EHR data weekly and surfaces potential trial-eligible patients to research coordinators for review.

Stakeholder Map

| Name/Role | Power | Interest | Quadrant | Role | Stance | Key Concern | | --- | --- | --- | --- | --- | --- | --- | | VP of Research Operations | High | High | Manage Closely | Champion | Supportive | "Will this help us hit our enrollment targets?" | | CISO | High | Low | Keep Satisfied | Gatekeeper | Neutral | "Is patient data handled correctly? HIPAA?" | | Director of Clinical Informatics | Medium | High | Manage Closely | Influencer + Gatekeeper | Skeptic | "We tried a similar tool 3 years ago and it didn't work." | | Lead Oncology Research Coordinator | Low | High | Keep Informed | End User + Influencer | Supportive | "I want a tool that actually understands eligibility criteria, not just keyword matching." | | IRB Chair | High | Medium | Keep Satisfied | Gatekeeper | Neutral | "Does any aspect of this require IRB review?" | | Principal Investigator (oncology) | Medium | High | Keep Informed | Influencer | Supportive | "Will coordinators actually trust the output?" |

Key Lessons from This Deployment

  • The Director of Clinical Informatics was the key stakeholder. Her skepticism was rooted in a real past failure, not resistance to AI in general. Addressing it required a live demo with her team's actual eligibility criteria, not generic product demos. Once converted, she became the second strongest champion in the account.
  • The IRB question came up early and the answer mattered. The product was purely a coordinator decision-support tool with no autonomous patient contact, so it did not require IRB review. Having Legal and Compliance confirm this in writing before the CISO security review prevented a 2-month delay.
  • End user trust was built through override visibility. We showed coordinators their override rate weekly. When they saw they were overriding 18% of recommendations in month 1 (mostly due to criteria nuances the model didn't capture), they felt heard. By month 3, the model had been refined based on their overrides and the rate dropped to 9%. Sharing that story at the quarterly check-in was the most effective renewal prep activity we did.

This canvas is based on patterns from AI deployments in Life Sciences & Healthcare. The specifics will differ by organization. The underlying stakeholder dynamics rarely do. Last updated: March 2026.

More on this

Further Reading